If not administered properly, health experts say medications like Ozempic, Mounjaro, and Wegovy can cause gastrointestinal ...
People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...
A systematic review and meta-analysis of five studies suggested that patients on GLP-1 receptor agonists were more likely to ...
A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!
A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...
Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary ...
SGLT-2 inhibitors and GLP-1 receptor agonists are linked to a reduced risk of COPD exacerbations in patients with type 2 ...
Health and Me on MSN3d
GLP-1 Drugs Could Be Used To Treat Chronic Kidney DiseaseA latest research led by Dr Shuyao Zhang, an assistant professor of internal medicine at UT Southwestern in Dallas reveal the ...
Sodium-glucose cotransporter 2, or SGLT2, inhibitors and glucagon-like peptide-1 receptor agonists lowered the risk for COPD exacerbation in adults with the disease and type 2 diabetes, researchers ...
Age differences are seen in the efficacy of treatments for type 2 diabetes, according to a study published online Feb ...
Compared to another common class of kidney medications, called DPP4is, GLP1-RA medications did better in helping slow the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback